Related Experiment Video
Updated: Aug 7, 2025
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
PAK5 is a potential target in myelodysplastic syndrome through interacting with LMO2 and GATA1
Xiaoyan Pan1, Dawei Liu2, Minchao Ying3
1Department of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, 310009 Hangzhou, China. panxiaoyan@zju.edu.cn.
Abstract:
Myelodysplastic syndrome (MDS) is a neoplastic heterogeneous and pre-leukemic disease with poor clinical outcome due to the failure of current chemotherapeutic strategies to target leukemic stem cells. Recently, we find that p21-activated kinase 5 (PAK5) overexpresses in MDS patients and leukemia cell lines. The clinical and prognostic value of PAK5 in MDS is unclear although it has anti-apoptosis ability and can promote cell survival and mobility in solid tumors. In this study, we find that LMO2 is co-expressed with PAK5 in the aberrant cells from MDS, and mitochondria-localized PAK5 can translocate into cell nucleus upon fetal bovine serum stimulation to interact with LMO2 and GATA1, which are important transcription regulators in hematological malignancies. Interestingly, without LMO2, PAK5 fails to bind GATA1 and facilitate GATA1 Ser161 site phosphorylation, indicating that PAK5 may be a key kinase in LMO2-associated hematopoietic diseases. Moreover, we find that PAK5 protein level in MDS is significantly higher than leukemia, and the data of 2095 leukemia samples from 'BloodSpot' database shows that PAK5 mRNA level in MDS is also increased obviously. Taken together, our findings suggest that PAK5-targeted strategies in clinical therapy have a potential value on MDS intervention.
Insights
p21-activated kinase 5 (PAK5) is elevated in myelodysplastic syndrome (MDS) and interacts with LMO2 and GATA1, suggesting PAK5 as a therapeutic target for MDS intervention.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myelodysplastic syndrome (MDS) is a pre-leukemic condition with poor prognosis.
- Current therapies fail to effectively target leukemic stem cells in MDS.
- p21-activated kinase 5 (PAK5) is overexpressed in MDS and leukemia, but its role is unclear.
Purpose of the Study:
- To investigate the clinical and prognostic value of PAK5 in MDS.
- To elucidate the molecular mechanisms of PAK5 in MDS pathogenesis.
- To explore PAK5 as a potential therapeutic target for MDS.
Main Methods:
- Analysis of PAK5 expression in MDS patients and leukemia cell lines.
- Investigation of PAK5 interaction with LMO2 and GATA1.
- Assessment of GATA1 phosphorylation at Ser161.
- Bioinformatic analysis of PAK5 mRNA levels in leukemia samples from the 'BloodSpot' database.
Main Results:
- PAK5 is co-expressed with LMO2 in aberrant MDS cells.
- Mitochondria-localized PAK5 translocates to the nucleus and interacts with LMO2 and GATA1 upon stimulation.
- PAK5 requires LMO2 to bind GATA1 and facilitate GATA1 phosphorylation.
- PAK5 protein and mRNA levels are significantly higher in MDS compared to leukemia.
Conclusions:
- PAK5 plays a crucial role in LMO2-associated hematopoietic malignancies.
- PAK5 is a key kinase in MDS pathogenesis.
- Targeting PAK5 may offer a potential therapeutic strategy for MDS intervention.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:23Abnormal Proliferation